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ABSTRACT
An Escherichia. coli-produced HPV-16/18 bivalent vaccine has been proved to be well-tolerated and highly
efficacious against diseases associated with vaccine HPV types. As a part of the multi-center, randomized,
double-blind phase III clinical trial, this lot-to-lot consistency study aimed to assess the safety and immuno-
genicity consistency of this novel HPV vaccine, which is also one of the objectives of the phase III trial. A total
of 3689 healthy women aged 18–45 years were enrolled and randomly assigned 1:1:1 to three lots of the HPV
vaccine groups. The primary outcomes were the IgG antibody level at 1 month after the last dose (month 7).
In the immunogenicity per-protocol set (PPS), almost all of the participants seroconverted at month 7 and
remained seropositive at month 42. For each paired comparison of the three lot groups, the two-sides of
90% CIs of GMC ratios for both IgG and neutralizing antibodies for HPV-16 and HPV-18 at month 7 were
within the equivalence interval [0.5, 2]. Lot consistency was also demonstrated at month 42. The majority of
recorded solicited reactions were mild or moderate. The incidences of solicited reactions of Lot 2 and Lot 3
were slightly higher than Lot 1. However, the incidences of solicited reactions of ≥ grade 3 and solicited
reactions by symptomswere all similar among the three lot groups. None of the SAEs was considered related
to vaccination by the investigator. In conclusion, this study demonstrates lot-to-lot consistency of the 3
consecutive lots of the E. coli-produced HPV-16/18 bivalent vaccine.
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Introduction
Human papillomavirus (HPV) is recognized as the cause of
almost all cervical cancer, a substantial proportion of other ano-
genital cancers and a subset of oropharyngeal cancers.1,2 It is
estimated that 4.5% of the new cancer cases worldwide are attri-
butable to HPV.3 Three prophylactic HPV vaccines are currently
available and had been introduced inmany countries. In countries
that had implemented national HPV vaccination programs with
high vaccination coverage rates, the prevalence and incidence of
HPV vaccine types related infections, cervical intraepithelial neo-
plasia grade 2+ (CIN2+), and anogenital warts decreased substan-
tially after national HPV vaccination program introduction.4-7
However, in most middle and lower income countries, the three
HPV vaccines are unaffordable due to the high cost, and the
limited production capacity affects availability.8
An Escherichia coli (E. coli)-produced bivalent human
papillomavirus (type 16 and 18) vaccine has been developed
and proved to be well-tolerated and highly efficacious against
HPV-16/18-associated high-grade genital lesions and persis-
tent infections in adult women aged 18–45 y in China.9-11
And the immune responses of this candidate HPV vaccine in
adolescent girls aged 9–14 y receiving two doses or girls aged
9–17 y receiving three doses were non-inferior to that in adult
women in an immunobridging study.12 The safety and immu-
nogenicity consistency in the production of this novel E. coli-
produced bivalent HPV vaccine still remains to be assessed.
Although there was no immunological correlate of protection
for HPV vaccines, antibody levels had been used to bridge the
efficacy in women to adolescents of which gynecologic examina-
tion could not be conducted,13-16 and to optimize the immuniza-
tion schedule17 or to provide insights into the potential for long-
termprotection; thus, it is also an appropriatemarker for assessing
lot consistency. Therewere several assays developed to evaluate the
type-specific HPV antibody levels, among which neutralizing
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antibodies measured by pseudovirion-based neutralization assay
(PBNA) was deemed as the gold standard for analyzing protective
antibodies.18,19 However, due to the complex and labor-
consuming characteristics of the PBNA assay, it could hardly be
used in large clinical trials with hundreds or thousands of samples.
Immunoglobin G (IgG) antibodies measured by HPV L1 virus-
like particle (VLP)-based enzyme-linked immunosorbent assays
(ELISAs) had been proved to be an acceptable surrogate for the
neutralizing antibody assay when measuring antibodies induced
by vaccination.20
The participants were randomized to receive three conse-
cutive lots of the HPV-16/18 bivalent vaccine or the control
vaccine (a commercialized hepatitis E vaccine) in the Phase III
efficacy clinical trial. This study was to analyse the safety and
immunogenicity consistency of three consecutive lots of vac-
cine, with HPV-16 and −18 specific IgG antibodies as the
primary immunogenicity endpoints and neutralizing antibo-
dies as the secondary immunogenicity endpoints.
Materials and methods
Study design and participants
This lot-to-lot consistency study was a part of the multi-center,
randomized, double-blind, placebo-controlled phase III clinical
trial which was to assess the efficacy of the E. coli-produced
HPV-16/18 bivalent vaccine in adult women (NCT01735006).
This study was conducted at four study centres including Cancer
Hospital Chinese Academy of Medical Sciences (having two
sites: Xinmi city in Henan, Yangcheng city in Shanxi), Peking
University People’s Hospital (one site: Fengning city in Hebei),
Jiangsu Provincial Centre for Disease Control and Prevention
(one site: Funing city in Jiangsu Province), and Guangxi Liuzhou
Centre for Disease Control and Prevention (one site: Liuzhou
city in Guangxi). The study was approved by the Independent
Ethics Committees of each center (12-72/606, 2012–48, 2012044,
IRB00001594) and conducted in accordance with the Good
Clinical Practice and Chinese regulatory requirements.
The aim of this study is to evaluate lot-to-lot consistency of
the test HPV bivalent vaccine which is one of the objectives of
the phase III clinical trial. Healthy adult women aged 18 to 45
years with intact cervix and without acute cervicitis and acute
lower reproductive tract infections were eligible for the inclu-
sion. The main study exclusion criteria were: pregnancy;
lactation; history of severe internal diseases; history of sexually
transmitted diseases; receipt of any HPV vaccines. Detail
eligibility criteria had been previously described.11
Study of vaccines
The test bivalent HPV-16/18 vaccine has been described in
the previous study.9,10,21 A 0.5 mL dose of test vaccine con-
tains 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs
expressed in E. coli which were adsorbed to 208 μg of alumi-
num adjuvant. Three Lots of test bivalent HPV vaccine (Lot1,
B20120404; Lot2, B20120405; Lot 3, B20120506) were used in
the study. The placebo vaccine was commercialized hepatitis
E vaccine (Hecolin®) contains 30 μg of E. coli-produced
recombinant hepatitis E virus capsid protein and 277 μg of
aluminum adjuvant (0.5mL/dose). The test vaccine and pla-
cebo vaccine were repackaged and supplied in coded single-
dose vials with identical appearance.
Randomization
Participants were stratified by age with 2 age groups (18–26
y and 27–45 y) and then randomly assigned 1:1 to receive
either the HPV-16/18 vaccine or the control hepatitis
E vaccine. The randomization lists were generalized by SAS
software (version 9.1, SAS Institute, Cary, NC) based on block
size of 12, including 6 random numbers for 3 lots of the study
vaccines (2 random numbers per lot) and 6 numbers for the
control vaccines; thus, the participants had been also rando-
mized to receive the three lots of HPV vaccine, with ratio of
1:1:1. All participants and investigators were blinded during
the whole study.
Immunogenicity assessments
Serum samples of all the participants were collected at day 0
and month 7 and serum samples of those from the Xinmi site
were also collected at month 42. Month 7 and 42 serum
samples were subjected to secondary blinding by persons
not involved in the clinical study under the supervision of
non-blinded statisticians before testing. HPV16/18 IgG anti-
bodies were tested using the same reagent lot by the National
Institute for the Control of Pharmaceutical and Biological
Products within the same time period by the same testing
team. Levels of IgG antibody against HPV-16 and −18 were
measured by E. coli-expressed HPV L1 VLP-based ELISA with
a cutoff value of 3.0 IU/mL for HPV-16 and 2.1 IU/mL for
HPV-18.11 Briefly, 96-well microtiter plates were coated with
HPV 16 VLPs or HPV 18 VLPs produced in E. coli. Diluted
serum samples were added and after incubation and wash,
horse-radish peroxidase-conjugated goat anti-human IgG was
added. After incubation and a second wash, tetramethylben-
zidine was added. Following incubation, the reactions were
stopped with the addition of H2SO4, and the optical density
(OD) was read at 450/620 nm. Serum dilutions were adjusted
so that the readings were within the linear range of the assay
and the titers were calculated using freeze-dried serum as
standard which is calibrated by World Health Organization
international standards for antibodies against HPV-16
(NIBSC code 05/134) or HPV-18 (NIBSC code 10/140). The
antibody level for negative serum sample was arbitrarily set to
half of the cutoff value. HPV16/18 neutralizing antibodies
were tested using same reagent lot by Xiamen Innovax
Biotech CO., LTD within same time period by same testing
team. PBNA was employed to measure neutralizing antibodies
against HPV-16 and −18 with a cutoff value of 20 YU/mL.20,22
The serum samples to be tested were serially diluted and
dilutions incubated at room temperature with HPV-16 or
HPV-18 pseudovirions produced by co-transfecting human
embryonic kidney (293FT) cells with plasmids encoding for
HPV L1, HPV L2, and green fluorescent protein (GFP). Then,
the serum-pseudovirus mixtures were added to 293FT cell
monolayers and cultured for three days. A positive sample
was defined as one that caused a 50% reduction in green
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fluorescent protein (GFP) expression compared with the
negative control, and the neutralizing titers were defined as
the highest dilution of the positive samples. The neutralizing
titers of the negative samples were set at 1:10, which is half of
the starting serum dilution. All the serum samples at day 0
were qualitatively tested for IgG antibodies, and all the sam-
ples of month 7 and month 42 were quantitatively tested for
IgG antibodies. Only samples from the Xinmi site at month 0
were further quantitatively tested for IgG antibodies, and only
samples from Xinmi site at month 0 and month 7 were
measured for neutralizing antibodies.
HPV DNA assessment
Methods of HPV DNA assessment had been described
previously.11 In brief, cervical swab was collected for each
women pre-vaccination and at month 7 by trained gynecologist.
Those with abnormal cytology diagnosis might be referred to
colposcopy and biopsy if needed. The satisfying swabs, and
biopsy samples with diagnosis of grade I or higher cervical
intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia
(VIN), and/or vaginal intraepithelial neoplasia (VaIN), were
tested for HPV DNA by HPV DNA enzyme immunoassay
method (Labo Biomedical Products, the Netherlands), positive
samples would be further typed by reverse hybridization line
probe assay (Labo Biomedical Products, Netherlands, based on
licensed Innogenetics LiPA technology) to detect 14 oncogenic
and 11 nononcogenic HPV types. In addition, all HPV positive
samples were also tested byHPV-16 and −18 specific polymerase
chain reactions (PCRs) (HPV TS16/18, Labo Biomedical
Products, Netherlands). A positive result for HPV-16 or HPV-
18 was defined as the presence of the relative type of HPV DNA
by LiPA or HPV TS16/18.
Safety assessment
The participants were requested to stay for at least 30 min
after each vaccination, any adverse reactions observed were
documented by the investigators. All the women were trained
to record all of the adverse reactions/events (AEs) that
occurred after each vaccination in a diary card, including
the solicited local and general symptoms for up to 7 days
and unsolicited adverse events in 30 days after each dose. All
the women were face-to-face followed-up or through phone
call for at least twice in 7 days and for another one time
during day 8 to day 30 after each vaccination. Serious adverse
events (SAEs) were recorded for the entire duration of the
whole trial.
Statistical analysis
Sample size was determined according to the efficacy end-
point assessment as previously described.11 For lot-to-lot con-
sistency analysis, assuming 20% non-evaluable subjects (loss
to follow-up, baseline seropositive and DNA positive for
HPV-16 or HPV-18), 588 subjects per group were needed to
conclude consistency between the three lots with an overall
power of over 90%. The total sample size for the phase III
clinical trial were over 6000, which is sufficient to observe the
differences between the lots. The primary analysis was based
on the per-protocol set (PPS) for immunogenicity in the
vaccine group which included the participants who were
seronegative for the relative antibodies at baseline, were nega-
tive for relevant types of HPV DNA from day 0 through
month 7, provided evaluable serum samples at day 0 and
month 7, received all three doses of vaccine according to the
protocol, and had no major protocol deviations. To assess the
lot-to-lot consistency of geometric mean concentration
(GMC), the 90% confidence intervals (CIs) of the GMC ratios
of IgG and neutralizing antibodies at month 7 were calculated
for each pair of vaccine lots (Lot 2 vs. Lot 1, Lot 3 vs. Lot 1,
Lot 3 vs. Lot 2) with analysis of covariance (ANCOVA)
model. GMC ratios for IgG antibodies at month 7 were
adjusted by ANCOVA model with logarithmic antibody titer
as the dependent variable, and Lot, study site and Lot*study
site interaction as independent variable. Consistency was
reached if the two-side 90% CIs of GMC ratio within the
[0.5, 2] interval.
All participants were included in safety analysis if they
received at least one dose of vaccine. All statistical analyses
were performed by SAS 9.2 software (SAS Institute,
Cary, NC).
Result
Study population
From November 22, 2012, to April 1, 2013, a total of 7372
participants were enrolled and randomly assigned to receive
the HPV-16/18 vaccine (3689 women) or hepatitis E vaccine
(placebo, 3683 women). Of the 3689 participants in the HPV
vaccine group, 1230, 1230 and 1229 women were randomly
assigned to the Lot 1, Lot 2 and Lot 3 groups, respectively
(Figure 1). There were one woman in each of the three lot
groups who received a wrong vaccine, vaccine of other lot or
the placebo, by mistakes during the whole vaccination course,
thus, these three women were excluded and leaving 3686
subjects in the safety analysis set. The baseline characteristics
of subjects, including age, seroprevalence, and GMC of HPV-
16/18 specific IgG and neutralizing antibodies, prevalence of
HPV-16/18 DNA was balanced among the three groups,
which were summarized in Table 1.
Immunogenicity
In the immunogenicity PPS cohort who received three doses
of the HPV-16/18 vaccine according to protocol and were
seronegative for the relative antibody at entry, almost all of
the participants seroconverted at 1 month after the last dose
(month 7), with seroconversion rates for HPV-16 IgG of all
the three lots was between 99.9%-100.0% and for HPV-18
were between 99.8%-100.0%. At month 42, all the participants
from Xinmi site in the PPS cohort remained seropositive for
HPV-16 IgG, and more than 98.8% of them were seropositive
for HPV-18 IgG. For neutralizing antibodies, all the partici-
pants except for one in Lot 2 group seroconverted for both
HPV types at month 7 in the PPS cohort of Xinmi site
(Table 2).
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At month 7, the GMCs and 95%CI for HPV-16 IgG was 779.7
IU/mL (741.9, 819.3), 789.2 IU/mL (749.0, 831.4), and 802.9 IU/
mL (763.1, 844.8); for HPV-18 IgG was 265.7 IU/mL (253.5,
278.5), 270.3 IU/mL (256.7, 284.6) and 267.7 IU/mL (255.1,
280.9) in the PPS cohort of Lot 1, Lot 2 and Lot 3 group separately.
TheGMCs of neutralizing antibodies toHPV-16 were 3313.8 YU/
mL (2977.0, 3688.6), 3165.9 YU/mL (2798.7, 3581.1) and 3171.2
YU/mL (2835.7, 3546.5), and to HPV-18 were 1720.2 YU/mL
(1516.6, 1951.2), 1476.5 YU/mL (1297.9, 1679.7) and 1658.5 YU/
mL (1460.8, 1883.0) for the three lots (Table 2). For each paired
Figure 1. Study flow chart. PPS: per-protocol set.
Table 1. Baseline characteristics of participants in the three vaccine lot groups.
Characteristic Lot 1 (n = 1230) Lot 2 (n = 1230) Lot 3 (n = 1229) Total (n = 3689)
Age (years, mean ± SD) 30.0 ± 7.3 30.1 ± 7.6 30.0 ± 7.4 30.0 ± 7.4
Age group (n, %)
18–26 621 (50.5) 620 (50.4) 620 (50.4) 1861 (50.4)
27–45 609 (49.5) 610 (49.6) 609 (49.6) 1828 (49.6)
Seropositive IgG antibody (n, %)
HPV16 370 (30.1) 361 (29.3) 375 (30.5) 1106 (30.0)
HPV18 217 (17.6) 211 (17.2) 189 (15.4) 617 (16.7)
Mean IgG antibody level of seropositive participants (GMC, 95%CI)
HPV16 7.4(6.3, 8.8) 6.8(6, 7.7) 6.8(5.8, 7.9) 7.0(6.4, 7.7)
HPV18 4.7(3.8, 5.9) 4.5(3.5, 5.6) 4.7(3.8, 5.8) 4.6(4.1, 5.2)
Seropositive neutralizing antibody (n, %)
HPV16 158 (12.8) 158 (12.8) 151 (12.3) 467 (12.7)
HPV18 68 (5.5) 62 (5.0) 56 (4.6) 186 (5.0)
Mean neutralizing antibody level of seropositive participants (GMC, 95%CI)
HPV16 42.6(28.8, 62.9) 37.2(24.9, 55.5) 47.6(30.7, 73.6) 42.0(33.6, 52.4)
HPV18 30.8(18.1, 52.4) 47.6(28.5, 79.5) 23.3(18.4, 29.5) 32.0(25.1, 40.9)
HPV DNA positive from day 0 to month 7 (n, %)
HPV16 45 (3.7) 50 (4.1) 46 (3.7) 141 (3.8)
HPV18 22 (1.8) 17 (1.4) 14 (1.1) 53 (1.4)
GMC: Geometric mean concentration.
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comparison of the three Lot groups (Lot 2 vs. Lot 1, Lot 3 vs. Lot 1
and Lot 3 vs. Lot 2), the two-sides of 90% CIs of GMC ratios for
both IgG and neutralizing antibodies for both HPV-16 and HPV-
18 at month 7 were within the equivalence interval [0.5, 2]
(Table 3). Reverse cumulative curves for IgG and neutralizing
antibody titers of the three lots groups at month 7 were almost
overlapped (Figure 2). At month 42, both HPV-16 and HPV-18
IgG concentrations of the three lot groups decreased to around
10% of the peak levels at month 7, while they remained consistent
with GMC ratios remaining within the equivalence interval (Table
3). In those baselines seropositive participants who received three
doses vaccine according to the protocols and had no major pro-
tocol deviations, HPV-16 and HPV-18 IgG antibody levels were
also comparable at month 7 and month 42 (Table 4).
Safety
As shown in Table 5, the majority of solicited and unsolicited
events were mild or moderate. The proportion of women
reported solicited AEs of grade 3 or more were 0.7%, 1.1%
and 0.8% in Lot 1 to Lot 3 groups (P = 0.41), which were
mainly induration, redness, swelling, and fever. The incidence
of any solicited adverse events of Lot 2 group (65.6%) were
similar to Lot 3 (63.0%), while slightly higher than Lot 1
(60.5%). However, the incidence of solicited adverse events by
symptoms were all similar among three lots groups. Injection
site pain was the most frequent local adverse event, reported in
33.3% to 35.2% of participants in the three lots groups. Fever
was the most common systemic adverse events (33.4% to
36.2%). During the entire study, SAEs were reported in 6.3%,
5.4% and 5.0% participants in Lot 1 to Lot 3 groups (P = .39).
Three deaths reported during the entire study, with one in Lot
1 group and two in Lot 3 group. One participant with a history
of type 2 diabetes (for >10 years) in Lot 1 died from diabetic
ketoacidosis at 14 months post the third injection. In Lot 3, one
participant made suicide by taking poison at 13 days post the
first injection and one died from traffic accidents at 24 months
after last injections. None of the SAEs was considered related to
vaccination by the investigator.
Discussion
In this multi-center, randomized, double-blind, placebo-
controlled phase III clinical trial, we demonstrated the safety
and immunogenicity consistency of the three consecutive lots
of E. coli-produced HPV-16/18 bivalent vaccines, which indi-
cated the stability in the production process of this novel
vaccine.
Although neutralizing antibodies measured by PBNA was
thought as the gold standard for analyzing protective
antibodies,18,19 and should be the most suitable index for
evaluating lot-to-lot consistency of immunogenicity, due to
its complexity and low throughput, it was set as the secondary
endpoint for analysis and measured only samples of
a subgroup (Xinmi site) of the whole cohorts. HPV type-
specific IgG antibodies were designed as the primary end-
point, as it is a highly reproducible method and correlated
well with the neutralizing antibodies when testing post-
vaccination serum samples.20 Data showed that all the three
consecutive lots of HPV vaccine were highly immunogenic
Table 2. Immuno-response at month 7 among the three lot groups (PPS for immunogenicity).
Month 7 Month 42#
Seroconversion Seropositivity
Assay* Group N n % (95% CI) GMC (95% CI) N n % (95% CI) GMC (95% CI)
IgG antibody
HPV16 Lot 1 776 776 100.0 (99.5, 100.0) 779.7 (741.9, 819.3) 134 134 100.0 (97.3, 100.0) 104.9 (89.9, 122.5)
Lot 2 767 766 99.9 (99.3, 100.0) 789.2 (749.0, 831.4) 135 135 100.0 (97.3, 100.0) 91.3 (81.2, 102.7)
Lot 3 757 757 100.0 (99.5, 100.0) 802.9 (763.1, 844.8) 134 134 100.0 (97.3, 100.0) 86.6 (75.7, 99.0)
HPV18 Lot 1 929 928 99.9 (99.4, 100.0) 265.7 (253.5, 278.5) 161 160 99.4 (96.6, 100) 21.8 (18.9, 25.0)
Lot 2 926 924 99.8 (99.2, 100.0) 270.3 (256.7, 284.6) 167 165 98.8 (95.7, 99.8) 21.8 (19.0, 24.9)
Lot 3 946 946 100.0 (99.6, 100.0) 267.7 (255.1, 280.9) 170 168 98.8 (95.8, 99.9) 21.5 (18.7, 24.7)
Neutralizing antibody $
HPV16 Lot 1 188 188 100.0 (98.1, 100.0) 3313.8 (2977.0, 3688.6) NA NA NA NA
Lot 2 186 185 99.5 (97.0, 100.0) 3165.9 (2798.7, 3581.1) NA NA NA NA
Lot 3 191 191 100.0 (98.1, 100.0) 3171.2 (2835.7, 3546.5) NA NA NA NA
HPV18 Lot 1 204 204 100.0 (98.2, 100.0) 1720.2 (1516.6, 1951.2) NA NA NA NA
Lot 2 199 198 99.5 (97.2, 100.0) 1476.5 (1297.9, 1679.7) NA NA NA NA
Lot 3 198 198 100.0 (98.2, 100.0) 1658.5 (1460.8, 1883.0) NA NA NA NA
*The unit was IU/mL for IgG antibody and YU/mL for neutralizing antibodies.
#Only samples from Xinmi site were tested for IgG antibodies at month 42.
$Only samples from Xinmi site at month 7 were tested for neutralizing antibodies.
PPS: per-protocol set; GMC: Geometric mean concentration.
Table 3. Equivalence analysis of GMC at month 7 (PPS for immunogenicity).
Assay Comparisons
GMC ratio at month 7
(90% CI)
GMC ratio at month 42
(90% CI)
IgG antibody
HPV16 Lot 2 vs Lot 1 1.00(0.93, 1.07) * 0.87(0.74, 1.02)
Lot 3 vs Lot 1 1.02(0.95, 1.09) * 0.82(0.70, 0.97)
Lot 3 vs Lot 2 1.02(0.95, 1.09) * 0.95(0.81, 1.11)
HPV18 Lot 2 vs Lot 1 1.01(0.95, 1.08) * 1.00(0.85, 1.18)
Lot 3 vs Lot 1 1.01(0.94, 1.08) * 0.99(0.84, 1.16)
Lot 3 vs Lot 2 1.00(0.93, 1.07) * 0.99(0.84, 1.16)
Neutralizing antibody
HPV16 Lot 2 vs Lot 1 0.96(0.83, 1.09) NA
Lot 3 vs Lot 1 0.96(0.84, 1.09) NA
Lot 3 vs Lot 2 1.00(0.88, 1.15) NA
HPV18 Lot 2 vs Lot 1 0.86(0.74, 1.00) NA
Lot 3 vs Lot 1 0.96(0.83, 1.12) NA
Lot 3 vs Lot 2 1.12(0.97, 1.31) NA
*GMC ratio for IgG antibodies at month 7 was adjusted by ANCOVA model with
logarithmic antibody titer as the dependent variable, and Lot, study site and
Lot*study site interaction as independent variable. GMC: Geometric mean
concentration. PPS: per-protocol set.
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and produced high level of both HPV-16/18 specific IgG and
neutralizing antibodies among women aged 18 to 45 years.
The GMC ratios of HPV-16 and HPV-18 IgG antibodies at
month 7 and month 42 ranged from 0.82 to 1.02, which all
met the predefined equivalence criterion. The data also indi-
cated the three lots of HPV vaccines induced consistent pro-
tective neutralizing antibodies. The seroconversion rates of all
the three consecutive lots for IgG and neutralizing antibodies
were over 99.5% at month 7 and seropositive rate for IgG
antibodies remained over 98.8% at month 42, which is similar
to the marketed HPV vaccine in Chinese women23,24 and
indicated similar immuno-persistency for the three lots.
Due to the different assays used in HPV vaccine clinical
trials to measure different subsets of the constellation of
antibodies induced by VLP vaccine25 and lack of controlled
comparisons, it is difficult to make direct comparison of
immunogenicity profiles of test vaccine and market vaccines.
However, similar to the market vaccines, peak IgG levels at
month 7 were over 100-fold (for HPV-16) and 50-fold (for
HPV-18) higher than those induced by natural infection, then
declined approximately 10-fold 1 year later and reached
a plateau level over the next 2 years.11,25 At month 7 after
vaccination, the peak neutralizing antibody levels against
HPV-16 and HPV-18 were also over 70-fold and 50-fold
higher than after natural infection. In addition, the efficacies
against high-grade genital lesions and persistent infection
were 100.0% (95%CI: 55.6–100.0%) and 97.8% (95%CI: 87.-
1–99.9%), respectively, in the per-protocol cohort, which is
also similar to the marketed HPV vaccines.26,27 These data
indicating the E. coli-produced bivalent HPV-16/18 vaccine is
a viable substitute for the commercial vaccine in terms of
efficacy profile.
This bivalent HPV vaccines were well tolerated with most AEs
mild or moderate and the safety profile was comparable between
three lots. Injection site pain and fever were the most frequently
reported local and systemic reactions, and the majority of them
Figure 2. Reverse cumulative curves for IgG and neutralizing antibody levels of the three lot groups (per-protocol set) at month 7. Panel A: HPV-16 IgG antibody;
Panel B: HPV-18 IgG antibody; Panel C: HPV-16 neutralizing antibody; Panel D: HPV-18 neutralizing antibody.
Table 4. Immuno-response at month 7 and 42 among three lots groups in participants who were seropositive at baseline*.
Month 7 Month 42
Seroconversion Seropositivity
Assay Group N n %(95%CI) GMC (95%CI) N n %(95%CI) GMC (95%CI)
HPV-16 IgG Lot 1 62 62 100.0(94.2, 100.0) 709.2(599.7, 838.7) 56 56 100.0(93.6, 100.0) 137.6(108.0, 175.2)
Lot 2 52 51 98.1(90.0, 100.0) 756.0(578.1, 988.8) 48 48 100.0(92.6, 100.0) 127.1(101.9, 158.4)
Lot 3 60 60 100.0(94.0, 100.0) 929.9(783.8, 1103.2) 56 56 100.0(93.6, 100.0) 141.6(116.1, 172.7)
HPV-18 IgG Lot 1 30 30 100.0(88.4, 100.0) 339.8(265.6, 434.6) 29 29 100.0(88.1, 100.0) 40.6(29.3, 56.1)
Lot 2 21 21 100.0(83.9, 100.0) 245.9(180.5, 335.1) 19 19 100.0(82.4, 100.0) 33.5(20.2, 55.7)
Lot 3 19 19 100.0(82.4, 100.0) 265.3(179.8, 391.5) 19 19 100.0(82.4, 100.0) 27.4(19.3, 38.9)
*Participants who were seropositive for the relative IgG antibody at baseline, received three doses of vaccine according to the protocols, and had no major protocol
deviations.
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were mild or moderate. The incidence of ≥ grade 3 AEs among
three lots were generally low and comparable from 0.7% to 1.2%
for solicitedAEs and from0.4% to 0.7% for unsolicitedAEs, in line
with findings from clinical trials of marketed HPV vaccines which
were conducted in China.23,24,28 No SAE or death was consider
vaccine-related during the entire study.
The strength of this study was the randomized controlled
design with a large sample size, and both HPV type 16/18-
specific IgG by ELISA and neutralizing antibodies by PBNA
were assessed to evaluate the lot-to-lot immunogenicity con-
sistency of this E. coli-produced HPV-16/18 bivalent vaccine,
which would make the conclusion more reliable. However, the
neutralizing antibody levels at month 7 and the IgG antibody
levels at month 42 are only available for a subset in this study.
Although the sample size for neutralizing antibody at month 7
and IgG antibody at month 42 was small (a smaller sample
size will lead to a wider confidence interval), the 90% CIs of
GMC ratios were still within the equivalence interval [0.5, 2].
Table 5. Incidence of adverse events (safety analysis).
Lot 1 (N = 1229) Lot 2 (N = 1229) Lot 3 (N = 1228)
Symptom N (%) N (%) N (%) P value
Solicited adverse events
Any 743(60.5) 806(65.6) 774(63.0) 0.03
≥Grade 3 8(0.7) 14(1.1) 10(0.8) 0.41
Local adverse events
Pain
Any 409(33.3) 433(35.2) 412(33.6) 0.54
≥Grade 3 0(0) 0(0) 0(0) NA
Induration
Any 85(6.9) 86(7) 90(7.3) 0.91
≥Grade 3 2(0.2) 5(0.4) 4(0.3) 0.57
Redness
Any 48(3.9) 50(4.1) 63(5.1) 0.27
≥Grade 3 1(0.1) 2(0.2) 3(0.2) 0.55
Swelling
Any 46(3.7) 48(3.9) 66(5.4) 0.09
≥Grade 3 4(0.3) 6(0.5) 5(0.4) 0.82
Rash
Any 2(0.2) 4(0.3) 5(0.4) 0.49
≥Grade 3 0(0) 0(0) 0(0) NA
Pruritus
Any 55(4.5) 46(3.7) 62(5) 0.29
≥Grade 3 0(0) 0(0) 0(0) NA
Systemic adverse events
Allery
Any 14(1.1) 15(1.2) 11(0.9) 0.72
≥Grade 3 0(0) 0(0) 0(0) NA
Nausea
Any 35(2.8) 50(4.1) 33(2.7) 0.10
≥Grade 3 0(0) 0(0) 0(0) NA
Fever
Any 410(33.4) 438(35.6) 445(36.2) 0.29
≥Grade 3 2(0.2) 4(0.3) 1(0.1) 0.52
Diarrhea
Any 34(2.8) 32(2.6) 36(2.9) 0.88
≥Grade 3 0(0) 1(0.1) 0(0) 1.00
Myalgia
Any 38(3.1) 42(3.4) 42(3.4) 0.87
≥Grade 3 0(0) 0(0) 0(0) NA
Cough
Any 61(5) 65(5.3) 63(5.1) 0.94
≥Grade 3 0(0) 0(0) 0(0) NA
Vomiting
Any 9(0.7) 15(1.2) 12(1) 0.47
≥Grade 3 0(0) 0(0) 0(0) NA
Fatigue
Any 86(7) 104(8.5) 85(6.9) 0.26
≥Grade 3 0(0) 0(0) 0(0) NA
Headache
Any 78(6.3) 87(7.1) 94(7.7) 0.45
≥Grade 3 0(0) 0(0) 0(0) NA
Unsolicited adverse events
Any 476(38.7) 452(36.8) 472(38.4) 0.56
≥Grade 3 5(0.4) 9(0.7) 5(0.4) 0.43
Serious adverse events
0 to 7 month 5(0.4) 9(0.7) 7(0.6) 0.56
During the entire study 77(6.3) 66(5.4) 62(5.0) 0.39
Death
0 to 7 month 0(0.0) 0(0.0) 1(0.08) 0.33
During the entire study 1(0.08) 0(0.0) 2(0.2) 0.33
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In conclusion, this study demonstrates lot-to-lot consistency
of the three consecutive lots of E. coli-produced HPV-16/18
bivalent vaccine, which could induce similar high level of
HPV-16/18 type-specific IgG and protective neutralizing anti-
bodies in healthy adult women with similar immune persistence.
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